ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2002

Randomized Clinical Trial in Pediatric Rheumatology: Are Parents and Patients in Equipoise?

Petra C.E. Hissink Muller1, Bahar Yildiz1, Cornelia F. Allaart2, Danielle M.C. Brinkman3, Marion A. J. Van Rossum4, J. Merlijn Van den Berg5, Lisette W.A. Van Suijlekom-Smit6, Rebecca Ten Cate1 and Martine C. de Vries7, 1Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center and Reade Institute, Amsterdam, Netherlands, 5Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Centre and Reade Institute, Amsterdam, Netherlands, 6Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, 7Medical Ethics and Health Law, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: etanercept, quality of care and randomized trials

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Session Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis and Other Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose:

It is an ethical requirement for setting up a randomized controlled trial (RCT) that the physician-investigator must have genuine uncertainty about the therapeutic options. This is called equipoise. Ideally patient-participants should also be in equipoise. In pediatric rheumatology, there are no data on whether this uncertainty also consists among parents and patients or if they have a specific preference for a particular treatment strategy. We conducted an interview study on the preferences of parents and children and the influence of the informed consent procedure on preferences in the setting of a randomized clinical trial in Juvenile Idiopathic Arthritis patients.

Methods:

Semi-structured interviews with parents (n = 23, 1 father and 22 mothers) and patients aged 12 and older (n = 7) participating in the BeSt for Kids study, a randomized clinical trial with three treatment strategies (arm 1: initial monotherapy with sulfasalazine or methotrexate, arm 2 : initial combination therapy with methotrexate and prednisone and arm 3: initial combination therapy with etanercept and methotrexate) in selected categories of newly diagnosed juvenile idiopathic arthritis patients.                                                                                                                                                 

Results:

All parents had a preference for a particular treatment strategy, 65% had a preference for the combination therapy with etanercept and methotrexate (arm 3). Five parents and two patients participated in the study to have a chance to be initially treated with etanercept, as initial treatment with etanercept in daily practice is currently neither possible nor reimbursed. The preference of parents and patients for arm 3 was based on their idea that etanercept is the best treatment for juvenile arthritis. The parents indicated that these beliefs were mainly based on knowledge they had gained through the internet and from experiences from people in their environment. Four parents had a preference for a non-prednisone arm. Aversion for prednisone was primary due to the fear for side-effects, such as weight gain. According to four parents, the physician-investigator had a preference for arm 3, but the vast majority of parents (n = 19) stated that the physician-investigator had no preferred strategy. Similar results emerged from the interviews with children.                                                  

Conclusion:

A large part of parents and children in the BeSt for Kids study are not in equipoise. In this study this is not caused by an assumed preference of the physician-investigator but by information on the various treatment possibilities obtained from other sources. The question is whether the absence of equipoise in parents and patients indicates that randomization is unethical or that this equipoise is not feasible in medical research.


Disclosure:

P. C. E. Hissink Muller,

Pfizer Inc,

2;

B. Yildiz,
None;

C. F. Allaart,
None;

D. M. C. Brinkman,
None;

M. A. J. Van Rossum,

Pfizer Inc,

9;

J. M. Van den Berg,
None;

L. W. A. Van Suijlekom-Smit,

Pfizer Inc,

2,

Abbott Immunology Pharmaceuticals,

2,

Pfizer Inc,

5,

Pfizer Inc,

9,

Dutch Arthritis Association,

2;

R. Ten Cate,

Pfizer Inc,

2;

M. C. de Vries,
None.

  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/randomized-clinical-trial-in-pediatric-rheumatology-are-parents-and-patients-in-equipoise/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.